TGBA01AD

TGBA01AD
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 17%
Biological half-life 4 hours

TGBA01AD is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[1] [2] As of May 2015, the Fabre-Kramer website lists TGBA01AD as being in phase II clinical trials.[2]

See also

References

External links



This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.